128 related articles for article (PubMed ID: 8412208)
21. Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.
Beenken SW; Sellers MT; Huang P; Peters G; Krontiras H; Dixon P; Stockard C; Listinsky C; Grizzle WE
Head Neck; 1999 Sep; 21(6):566-73. PubMed ID: 10449674
[TBL] [Abstract][Full Text] [Related]
22. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
23. Development of chemopreventive agents for bladder cancer.
Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16I():1-12. PubMed ID: 1305671
[TBL] [Abstract][Full Text] [Related]
24. Intermediate markers as surrogate endpoints in cancer research.
Schatzkin A
Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
[TBL] [Abstract][Full Text] [Related]
25. Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials.
Follen M; Schottenfeld D
Cancer; 2001 May; 91(9):1758-76. PubMed ID: 11335902
[TBL] [Abstract][Full Text] [Related]
26. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents.
Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
J Cell Biochem Suppl; 1997; 28-29():1-20. PubMed ID: 9589346
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
28. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
29. Chemoprevention for prostatic intraepithelial neoplasia.
Nelson PS; Gleason TP; Brawer MK
Eur Urol; 1996; 30(2):269-78. PubMed ID: 8875211
[TBL] [Abstract][Full Text] [Related]
30. Cytometric evidence that cervical intraepithelial neoplasia I and II are dysplasias rather than true neoplasias. An image analysis study of factors involved in the progression of cervical lesions.
Mariuzzi G; Santinelli A; Valli M; Sisti S; Montironi R; Mariuzzi L; Alberti R; Pisani E
Anal Quant Cytol Histol; 1992 Apr; 14(2):137-47. PubMed ID: 1590897
[TBL] [Abstract][Full Text] [Related]
31. Intermediate biomarkers of precancer and their application in chemoprevention.
Kelloff GJ; Malone WF; Boone CW; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16G():15-21. PubMed ID: 1469895
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
33. If there is gold in the labeling index hills, are we digging in the right place?
Aickin M
J Cell Biochem Suppl; 1994; 19():91-3. PubMed ID: 7823611
[TBL] [Abstract][Full Text] [Related]
34. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells.
Volgareva G; Zavalishina L; Andreeva Y; Frank G; Krutikova E; Golovina D; Bliev A; Spitkovsky D; Ermilova V; Kisseljov F
BMC Cancer; 2004 Aug; 4():58. PubMed ID: 15339339
[TBL] [Abstract][Full Text] [Related]
35. Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis.
Boone CW; Kelloff GJ
Cancer Surv; 1998; 32():133-47. PubMed ID: 10489626
[TBL] [Abstract][Full Text] [Related]
36. Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.
Bruno S; Torrisi R; Costantini M; Baglietto L; Fontana V; Gatteschi B; Melioli G; Nicolo G; Curotto A; Malcangi B; Bruttini GP; Varaldo M; Bruzzi P; Decensi A
J Cell Biochem; 1999 Dec; 76(2):311-21. PubMed ID: 10618647
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study.
Murakami T; Akazawa Y; Yatagai N; Hiromoto T; Sasahara N; Saito T; Sakamoto N; Nagahara A; Yao T
Diagn Pathol; 2018 Nov; 13(1):88. PubMed ID: 30458818
[TBL] [Abstract][Full Text] [Related]
38. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
39. Cancer: the role of extracellular disease.
Schwartz L; Balosso J; Baillet F; Brun B; Amman JP; Sasco AJ
Med Hypotheses; 2002 Apr; 58(4):340-6. PubMed ID: 12027530
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer chemoprevention: current challenges and a look toward the future.
Fabian CJ; Kimler BF
Clin Breast Cancer; 2002 Jun; 3(2):113-24. PubMed ID: 12123535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
